765 The first-in-class small molecule TREX1 inhibitor CPI-381 demonstrates type I IFN induction and sensitization of tumors to immune checkpoint blockade

• Jonathan Wilson,
• Lei Cui,
• Costa Salojin,
• Anna Gardberg,
• Valerie Vivat,
• Jeffrey Lauer,
• Nico Cantone,
• Jacob Stuckey,
• Florence Poy,
• Ingrid Almeciga,
• Richard Cummings,
• Julian Levell,
• Jennifer Rocnik,
• Patrick Trojer

Affiliations

Jonathan Wilson

General Surgery, Whittington Health NHS Trust, London, United Kingdom

Lei Cui

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Costa Salojin

Constellation Pharmaceuticals, Cambridge, MA, United States

Anna Gardberg

Constellation Pharmaceuticals, Cambridge, MA, United States

Valerie Vivat

Constellation Pharmaceuticals, Cambridge, MA, United States

Jeffrey Lauer

Constellation Pharmaceuticals, Cambridge, MA, United States

Nico Cantone

Constellation Pharmaceuticals, Cambridge, MA, United States

Jacob Stuckey

Constellation Pharmaceuticals, Cambridge, MA, United States

Florence Poy

Constellation Pharmaceuticals, Cambridge, MA, United States

Ingrid Almeciga

Constellation Pharmaceuticals, Cambridge, MA, United States

Richard Cummings

Constellation Pharmaceuticals, Cambridge, MA, United States

Julian Levell

Constellation Pharmaceuticals, Cambridge, MA, United States

Jennifer Rocnik

Constellation Pharmaceuticals, Cambridge, MA, United States

Patrick Trojer

Constellation Pharmaceuticals, Cambridge, MA, United States